As planned, the clinical trial application has been approved and thus a very important milestone has been reached when Lipum has manage to go from preclinical to clinal development for our drug candidate SOL-116. I´m very proud of the team and everyone who has contributed to this success with great dedication

Lipum is focused on a novel and unique way of treating chronic inflammatory diseases that we hope will satisfy a large and global medical need. We have successfully developed the biological drug candidate SOL-116, which is a fully humanized therapeutical antibody, and we now stand ready to exploit it through clinical as well as pre-clinical studies. Therefore, it is very important that we have now been able to secure further financing from committed and knowledgeable owners

I am looking forward to these events. We are approaching clinical trials of our biological lead candidate SOL-116 and industry meetings provide good opportunities to present our progress

Dr Bergström has valuable and extensive experience in pharmacology and clinical trials. Her strong drive and commitment will also certainly contribute to the success of our clinical development. She will be an important cog in our team, and I am delighted to welcome Helena

Another milestone has been reached and we are indeed pleased with the results that, as expected, confirms the safety and tolerability of our antibody SOL-116. We are now looking forward to the start of our first-in-man clinical study later this year

Sweden is at the forefront of bioanalytical chemistry and therefore I am very pleased that we have started cooperation with Pelago in Solna. This means a strengthening of our development work and the opportunity for more valuable results from clinical studies on our lead candidate SOL-116

We are already involved in a previous project and have a rewarding collaboration with the Cardiovascular Research Center. This new grant provides continued opportunities for the research collaboration, and it is fully in line with our plan to study additional indications for our drug candidate SOL-116

We are, according to plan, proceeding towards a significant milestone in our development and are indeed looking forward to start clinical studies in collaboration with QPS Netherlands later this year.

A significant milestone has been reached in the development of our drug candidate. We are pleased to have APL as our partner for the next step. It is also great that this work is in good hands locally at their site here in Umeå

Lipum's work ahead the first clinical study is continuing as planned and, in line with our strategy, we are now strengthening our team to identify additional indications for SOL-116 in parallel with the clinical program

We are facing the next step in Lipum's development and plan for the start of clinical trials in 2022. Then, of course, it is extremely valuable to have active owners who with industrial experience can support that development

I am very enthusiastic for the experience that Maria brings and that she takes a leader role for Lipum's competent team. This is a great step towards a successful clinical development phase for the company

Biological drugs are generally both tricky and expensive to develop compared to small molecules, but the chance of reaching the market is significantly better. We have now reached a milestone and taken a decisive step for the start clinical trials according to plan

We are very pleased with the progress both with regards to the results and the adherence to time plans for this mandatory work, which is required to reach our next milestone and start clinical studies.

Lipum has reached a stage when we are preparing for clinical trials. Important intermediate goals have been achieved during the first half of the year. Toxicology- and safety studies are progressing according to plan as well as the upscaling of the production process of our drug candidate SOL-116

It is a strength with Lipum's high scientific level and we congratulate Professor Hernell for the recognition of his scientific contributions

The contribution from Horizon 2020 has been central and giving us the opportunity to develop the drug candidate SOL-116. This has a new mechanism of action and potential to be the first in a new drug class for treatment of chronic inflammatory diseases